Usefulness of mycophenolic acid monitoring with PETINIA for prediction of adverse events in kidney transplant recipients

References

• KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9:S1–155.
   PubMedGoogle Scholar
• Ransom JT. Mechanism of action of mycophenolate mofetil. Ther Drug Monit 1995;17:681–4.
   PubMed Web of Science ®Google Scholar
• Shaw LM, Korecka M, Venkataramanan R, Goldberg L, Bloom R, Brayman KL. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003;3:534–42.
   PubMed Web of Science ®Google Scholar
• Hale MD, Nicholls AJ, Bullingham RE, Hene R, Hoitsma A, Squifflet JP, Weimar W, Vanrenterghem Y, Van de Woude FJ, Verpooten GA. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998;64:672–83.
   PubMed Web of Science ®Google Scholar
• van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, Hene RJ, Verpooten GA, Navarro MT, Hale MD, Nicholls AJ. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999;68:261–6.
   PubMed Web of Science ®Google Scholar
• Oellerich M, Shipkova M, Schutz E, Wieland E, Weber L, Tonshoff B, Armstrong VW, Members of the German study group on mycophenolate mofetil therapy in pediatric renal transplant recipients. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. Ther Drug Monit 2000;22:20–6.
   PubMed Web of Science ®Google Scholar
• Kiberd BA, Lawen J, Fraser AD, Keough-Ryan T, Belitsky P. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant 2004;4:1079–83.
   PubMed Web of Science ®Google Scholar
• Kuypers DR, de Jonge H, Naesens M, de Loor H, Halewijck E, Dekens M, Vanrenterghem Y. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther 2008;30:673–83.
   PubMed Web of Science ®Google Scholar
• Mourad M, Malaise J, Chaib Eddour D, De Meyer M, Konig J, Schepers R, Squifflet JP, Wallemacq P. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem 2001;47:1241–8.
   PubMed Web of Science ®Google Scholar
• Armstrong VW, Shipkova M, Schutz E, Weber L, Tonshoff B, Oellerich M, German Study Group on MMF therapy in pediatric renal transplant recipients. Monitoring of mycophenolic acid in pediatric renal transplant recipients. Transplant Proc 2001;33:1040–3.
   PubMed Web of Science ®Google Scholar
• Weber LT, Shipkova M, Armstrong VW, Wagner N, Schutz E, Mehls O, Zimmerhackl LB, Oellerich M, Tonshoff B. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002;13:759–68.
   PubMed Web of Science ®Google Scholar
• Borrows R, Chusney G, Loucaidou M, James A, Lee J, Tromp JV, Owen J, Cairns T, Griffith M, Hakim N, McLean A, Palmer A, Papalois V, Taube D. Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. Am J Transplant 2006;6:121–8.
   PubMed Web of Science ®Google Scholar
• Elbarbry FA, Shoker AS. Therapeutic drug measurement of mycophenolic acid derivatives in transplant patients. Clin Biochem 2007;40:752–64.
   PubMed Web of Science ®Google Scholar
• Beal JL, Jones CE, Taylor PJ, Tett SE. Evaluation of an immunoassay (EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatography assay. Ther Drug Monit 1998;20:685–90.
   PubMed Web of Science ®Google Scholar
• Schutz E, Shipkova M, Armstrong VW, Niedmann PD, Weber L, Tonshoff B, Pethig K, Wahlers T, Braun F, Ringe B, Oellerich M. Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites. Transplant Proc 1998;30:1185–7.
   PubMed Web of Science ®Google Scholar
• Premaud A, Rousseau A, Picard N, Marquet P. Determination of mycophenolic acid plasma levels in renal transplant recipients co-administered sirolimus: comparison of an enzyme multiplied immunoassay technique (EMIT) and liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2006;28:274–7.
   PubMed Web of Science ®Google Scholar
• van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, Holt DW, Kaplan B, Kuypers D, Meiser B, Tonshoff B, Mamelok RD. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006;28:145–54.
   PubMed Web of Science ®Google Scholar
• Vergara Chozas JM, Sáez-Benito Godino A, Zopeque Garcia N, García Pinteño S, Joumady I, Carrasco García C, Vara Gil F. Analytical validation of a homogeneous immunoassay for determination of mycophenolic acid in human plasma. Transplant Proc 2012;44:2669–72.
   PubMed Web of Science ®Google Scholar
• Jin MK, Cho JH, Kwon O, Hong KD, Choi JY, Yoon SH, Park SH, Kim YL, Kim CD. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience. Transplant Proc 2012;44:200–3.
   Google Scholar
• Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, Castro MC, David DS, David-Neto E, Bagnasco SM, Cendales LC, Cornell LD, Demetris AJ, Drachenberg CB, Farver CF, Farris AB III, Gibson IW, Kraus E, Liapis H, Loupy A, Nickeleit V, Randhawa P, Rodriguez ER, Rush D, Smith RN, Tan CD, Wallace WD, Mengel M, Banff meeting report writing committee. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014;14:272–83.
   PubMed Web of Science ®Google Scholar
• CLSI. Evaluation of precision of quantitative measurement procedures; approved guideline – 3rd ed. CLSI document EP05-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.
   Google Scholar
• CLSI. Evaluation of the linearity of quantitative measurement procedures; a statistical approach; approved guideline. CLSI document EP06-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2003.
   Google Scholar
• CLSI. Preliminary evaluation of quantitative clinical laboratory methods; approved guideline – 3rd ed. CLSI document E10-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2006.
   Google Scholar
• Broughton PM. Carry-over in automatic analysers. J Automat Chem 1984;6:94–5.
   PubMedGoogle Scholar
• Dasgupta A, Johnson M, Tso G. Mathematical equations to calculate true mycophenolic acid concentration in human plasma by using two immunoassays with different cross-reactivities with acyl glucuronide metabolite: comparison of calculated values with values obtained by using an HPLC-UV method. J Clin Lab Anal 2013;27:290–3.
   PubMed Web of Science ®Google Scholar
• Martiny D, Macours P, Cotton F, Thiry P, Gulbis B. Reliability of mycophenolic acid monitoring by an enzyme multiplied immunoassay technique. Clin Lab 2010;56:345–53.
   PubMed Web of Science ®Google Scholar
• Premaud A, Rousseau A, Le Meur Y, Lachatre G, Marquet P. Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring. Ther Drug Monit 2004;26:609–19.
   PubMed Web of Science ®Google Scholar
• Shipkova M, Schutz E, Armstrong VW, Niedmann PD, Oellerich M, Wieland E. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and EMIT. Clin Chem 2000;46:365–72.
   PubMed Web of Science ®Google Scholar
• Weber LT, Shipkova M, Armstrong VW, Wagner N, Schutz E, Mehls O, Zimmerhackl LB, Oellerich M, Tonshoff B. Comparison of the EMIT immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. Clin Chem 2002;48:517–25.
   PubMed Web of Science ®Google Scholar
• Dasgupta A, Tso G, Chow L. Comparison of mycophenolic acid concentrations determined by a new PETINIA assay on the dimension EXL analyzer and a HPLC-UV method. Clin Biochem 2013;46:685–7.
   PubMed Web of Science ®Google Scholar
• Shipkova M, Schutz E, Besenthal I, Fraunberger P, Wieland E. Investigation of the crossreactivity of mycophenolic acid glucuronide metabolites and of mycophenolate mofetil in the Cedia MPA assay. Ther Drug Monit 2010;32:79–85.
   PubMed Web of Science ®Google Scholar
• Westley IS, Ray JE, Morris RG. CEDIA mycophenolic acid assay compared with HPLC-UV in specimens from transplant recipients. Ther Drug Monit 2006;28:632–6.
   PubMed Web of Science ®Google Scholar
• Irtan S, Azougagh S, Monchaud C, Popon M, Baudouin V, Jacqz-Aigrain E. Comparison of high-performance liquid chromatography and enzyme-multiplied immunoassay technique to monitor mycophenolic acid in paediatric renal recipients. Pediatr Nephrol 2008;23:1859–65.
   PubMed Web of Science ®Google Scholar
• Le Meur Y, Borrows R, Pescovitz MD, Budde K, Grinyo J, Bloom R, Gaston R, Walker RG, Kuypers D, van Gelder T, Kiberd B. Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of the Transplantation Society consensus meeting. Transplant. Rev 2011;25:58–64.
   Google Scholar
• Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol 2003;43:866–80.
   PubMed Web of Science ®Google Scholar
• van Gelder T, Hesselink DA. Mycophenolate revisited. Transpl Int 2015;28:508–15.
   PubMed Web of Science ®Google Scholar
• Staatz CE, Tett SE. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Arch Toxicol 2014;88:1351–89.
   PubMed Web of Science ®Google Scholar
• van Hest RM, Mathot RA, Pescovitz MD, Gordon R, Mamelok RD, van Gelder T. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006;17:871–80.
   PubMed Web of Science ®Google Scholar